RxDoctor Payments Data

Raymond Allen, MD

Interventional Cardiology · Sioux Falls, SDNPI 1396733705

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Shockwave Medical, Inc at 29.3% of the total. Reporting peaked in 2024 at $227 and has fallen 89.3% since, to $24 in 2025.

$885in general payments, 2019–2025

Across 38 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$260
  • Asahi Intecc USA, Inc.$209
  • Boston Scientific$187
  • Abbott$110
  • Abiomed$78
  • W. L. Gore & Associates, Inc.$25
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$171,307
Medicare patients
1,154
Services billed
2,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$125,628
Repatha SureclickEvolocumab135$73,662
XareltoRivaroxaban45$39,647
JardianceEmpagliflozin23$19,814
Ezetimibe480$15,660
Praluent PenAlirocumab22$10,391
Repatha SyringeEvolocumab15$8,435
Rosuvastatin Calcium385$5,627
Valsartan108$3,209
ClopidogrelClopidogrel Bisulfate285$2,966
Metoprolol Succinate176$1,942
Enalapril Maleate67$1,779
Dofetilide13$1,106
Nitroglycerin PatchNitroglycerin30$1,092
Isosorbide Mononitrate ErIsosorbide Mononitrate108$1,085

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →